# MindRank AI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mindrank-ai

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.mindrank.ai/
- Total disclosed funding: $79M
- Latest round: Series B (Jul 8, 2026)
- Investors on record: 8

## About

Based in Hangzhou, China and founded in 2020, MindRank Ltd., trading under the name MindRank AI, provides artificial intelligence-driven drug discovery platforms for the biotechnology sector. In March 2021, the company's AI Pharma Solution was recognized by Deep Pharma Intelligence as one of the 11 Most Important AI Drug Development Breakthrough Achievements in the World 2018-2020. In 2022 and 2023, the Company has small molecule drugs approved by the U.S. FDA and China. Meanwhile, the company's partners include Medicilon, Antengene and other pharmaceutical companies. The CEO is Zhangming Niu. In July 2026, the company raised USD 52 million in series B funding. 

The company works with pharmaceutical enterprises to provide artificial intelligence-assisted drug design platforms, including the Molecule Arts Platform (MAP). This platform integrates biological, chemical, computational, and clinical data to support target research, molecular design, and multi-parameter optimization. The company also develops proprietary drug pipelines, such as the MDR-001 oral small-molecule GLP-1 receptor agonist for obesity and type 2 diabetes, and the MRANK-106 dual WEE1/YES1 kinase inhibitor for oncology. 
 
The company plans to use the Series B funding to support the continued advancement of its Molecule Arts Platform and the progression of its clinical and preclinical pipelines, including the Phase III clinical development of MDR-001 in China.

## Funding rounds

- Series B, Jul 8, 2026, $52M — Shenyin Wanguo Hongding Equity Investment Management, Cherami Investment Group, Star River Group, WinX Capital, Tailong VC
- Series A, Jul 18, 2023, $20M — Cherami Investment Group
- Series A, Dec 15, 2021 — Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners
- Angel, May 21, 2021, $7M — Sherpa Healthcare Partners

## Investors

- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Angel, Series A
- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Series A
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series A
- Cherami Investment Group (https://capitalatlas.ai/funds/cherami-investment-group) — Series A, Series B
- Shenyin Wanguo Hongding Equity Investment Management (https://capitalatlas.ai/funds/shenyin-wanguo-hongding-equity-investment-management) — Series B
- Star River Group — Series B
- WinX Capital — Series B
- Tailong VC (https://capitalatlas.ai/funds/tailong-vc) — Series B